Latest Period
Q2 2026
Security Snapshot
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) Institutional Ownership
CUSIP: 02043Q107
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
781
Shares (Excl. Options)
133,125,963
Price
$301.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ALNY on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 133,125,963
- Total 13F value
- $40,052,419,709
- Portfolio coverage rank
- 0.01%
- Share change
- +3,314,661
- Value change
- +$1,011,453,400
- Number of holders
- 781
- Shares outstanding
- 133,131,695
- SEC-reported price per share
- $205.48
- Insider filing price
- $205.48
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 02043Q107.
- 781 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 790 to 781 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $42,947,038,622 to $40,052,419,709.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 781 institutions filings for Q2 2026.
Security key
02043Q107
Latest holder period
Q2 2026
13F holders
781
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
ALNY full holder history
ALNYLAM PHARMACEUTICALS, INC. SEC filings
ALNYLAM PHARMACEUTICALS, INC. company facts
ALNYLAM PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02043Q107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ALNY
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | -14% | $4,875,294,782 | -$730,458,810 | 14,640,525 | -13% | FMR LLC | 31 Mar 2026 |
| Capital World Investors | 8.2% | $3,635,294,067 | 10,916,799 | Capital World Investors | 31 Mar 2026 | |||
| Capital Research Global Investors | 7.1% | +34% | $3,153,903,273 | +$833,388,444 | 9,471,181 | +36% | Capital Research Global Investors | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4% | $2,350,677,826 | 7,104,536 | Vanguard Capital Management | 31 Mar 2026 |
As of 30 Jun 2026, 781 institutional investors reported holding 133,125,963 shares of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY). This represents 100% of the company’s total 133,131,695 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 15,023,962 | +3.1% | 0.2% | $4,522,663,249 |
| Capital World Investors | 8.4% | 11,144,846 | +3.2% | 0.4% | $3,354,715,611 |
| BlackRock, Inc. | 8.2% | 10,907,675 | +4.4% | 0.05% | $3,283,537,489 |
| Capital Research Global Investors | 7.3% | 9,750,699 | +3% | 0.41% | $2,935,115,324 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9% | 6,538,390 | +0.73% | 0.09% | $1,968,251,542 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 6,029,478 | +1.4% | 0.04% | $1,815,053,762 |
| T. Rowe Price Investment Management, Inc. | 4.2% | 5,642,173 | +8.6% | 1.1% | $1,698,464,000 |
| Invesco Ltd. | 2.8% | 3,754,318 | +35% | 0.09% | $1,130,162,348 |
| STATE STREET CORP | 2.7% | 3,555,689 | +7% | 0.03% | $1,070,369,060 |
| JPMORGAN CHASE & CO | 2% | 2,675,517 | -58% | 0.05% | $785,318,336 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,635,840 | -0.92% | 0.04% | $791,345,610 |
| BAILLIE GIFFORD & CO | 1.8% | 2,439,889 | -2.2% | 0.67% | $734,479,786 |
| NORGES BANK | 1.7% | 2,271,813 | 0.07% | $683,883,867 | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.6% | 2,110,407 | +9% | 0.11% | $635,295,819 |
| Orbis Allan Gray Ltd | 1.5% | 1,987,407 | +49% | 2.1% | $598,269,130 |
| Dodge & Cox | 1.5% | 1,955,393 | +1.4% | 0.31% | $588,631,955 |
| TWO SIGMA INVESTMENTS, LP | 1.4% | 1,875,937 | -5.9% | 0.42% | $564,713,315 |
| AMERICAN CENTURY COMPANIES INC | 1.4% | 1,853,956 | +2.9% | 0.25% | $558,098,292 |
| Clearbridge Investments, LLC | 0.95% | 1,259,483 | -7.1% | 0.31% | $379,142,285 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.86% | 1,149,201 | -20% | 0.03% | $345,945,000 |
| D. E. Shaw & Co., Inc. | 0.83% | 1,104,109 | +4.3% | 0.21% | $332,369,932 |
| MORGAN STANLEY | 0.78% | 1,032,150 | +2.9% | 0.02% | $310,709,115 |
| BANK OF AMERICA CORP /DE/ | 0.75% | 994,476 | +2.9% | 0.02% | $299,367,191 |
| Legal & General Group Plc | 0.69% | 924,561 | -1.1% | 0.06% | $278,320,594 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.67% | 893,795 | +35% | 0.21% | $269,059,154 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 133,125,963 | $40,052,419,709 | +$1,011,453,400 | $301.03 | 781 |
| 2026 Q1 | 130,107,266 | $42,947,038,622 | -$452,033,358 | $330.87 | 790 |
| 2025 Q4 | 129,488,819 | $51,507,210,845 | -$543,273,038 | $397.65 | 845 |
| 2025 Q3 | 129,757,754 | $59,159,078,884 | -$749,369,667 | $456.00 | 814 |
| 2025 Q2 | 132,062,946 | $43,060,444,035 | +$1,728,282,756 | $326.09 | 645 |
| 2025 Q1 | 126,881,187 | $34,233,011,857 | -$90,968,751 | $270.02 | 615 |
| 2024 Q4 | 127,632,870 | $30,037,175,866 | -$216,265,374 | $235.31 | 587 |
| 2024 Q3 | 123,754,217 | $34,035,461,284 | +$1,116,635,795 | $275.03 | 559 |
| 2024 Q2 | 119,818,858 | $29,121,298,158 | +$1,425,600,934 | $243.00 | 514 |
| 2024 Q1 | 114,506,382 | $17,112,788,490 | -$462,345,987 | $149.45 | 488 |
| 2023 Q4 | 117,037,909 | $22,406,153,370 | -$144,088,009 | $191.41 | 491 |
| 2023 Q3 | 117,774,911 | $20,850,702,200 | -$144,549,642 | $177.10 | 445 |
| 2023 Q2 | 118,559,398 | $22,525,153,339 | -$212,624,410 | $189.94 | 469 |
| 2023 Q1 | 119,657,504 | $23,956,079,414 | +$6,809,245 | $200.32 | 469 |
| 2022 Q4 | 119,654,959 | $28,425,215,078 | -$3,086,850,614 | $237.65 | 477 |
| 2022 Q3 | 133,393,008 | $26,709,327,641 | +$3,401,526,639 | $200.16 | 479 |
| 2022 Q2 | 113,477,846 | $16,543,858,767 | -$67,066,647 | $145.85 | 405 |
| 2022 Q1 | 113,908,234 | $18,598,579,814 | +$320,228,126 | $163.29 | 417 |
| 2021 Q4 | 112,006,374 | $18,989,908,067 | +$63,928,357 | $169.58 | 420 |
| 2021 Q3 | 111,604,687 | $21,068,206,424 | -$147,043,437 | $188.81 | 395 |
| 2021 Q2 | 112,239,402 | $19,027,485,774 | +$501,915,844 | $169.52 | 390 |
| 2021 Q1 | 109,361,699 | $15,431,272,628 | +$204,818,578 | $141.19 | 381 |
| 2020 Q4 | 107,900,409 | $14,018,800,907 | -$114,208,967 | $129.97 | 353 |
| 2020 Q3 | 108,499,178 | $15,789,451,789 | -$460,283,345 | $145.60 | 347 |
| 2020 Q2 | 111,562,100 | $16,522,566,788 | +$489,977,680 | $148.11 | 363 |